Eisai Co., Ltd. (ESAIY) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Drug Manufacturers - Specialty & Generic उद्योग. कंपनी का मुख्यालय है Tokyo, Japan. वर्तमान CEO हैं Haruo Naito.
ESAIY के पास है IPO तिथि 2023-02-02, 11,067 पूर्णकालिक कर्मचारी, पर सूचीबद्ध Other OTC, बाजार पूंजीकरण $9.03B.
Eisai Co., Ltd. is a Tokyo-based pharmaceutical company founded in 1941 that engages in the research, development, manufacture, and commercialization of prescription medications across multiple therapeutic areas. The company's product portfolio includes Dayvigo for insomnia, Lenvima for various cancers including thyroid and renal cell carcinoma, Aricept for Alzheimer's disease, Halaven for breast cancer, and Fycompa for epilepsy, among other medications addressing neurology, oncology, gastroenterology, and other specialties. Eisai maintains a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin, an antibody drug conjugate. The company operates globally with a strong presence in Japan and serves both domestic and international markets through its research and manufacturing operations.
